Global Parkinson's Disease Therapeutics Market by Type (Intestinal Infusion, Oral, Subcutaneous), Drug Class (Anticholinergic, Carbidopa/Levodopa, COMT Inhibitor), Distribution Channel, End Use - Forecast 2024-2030

Report
186 Pages
March 2024
Region: Global
360iResearch™
ID: 5134266

The Parkinson's Disease Therapeutics Market size was estimated at USD 6.67 billion in 2023, USD 7.21 billion in 2024, and is expected to grow at a CAGR of 8.28% to reach USD 11.64 billion by 2030.

FPNV Positioning Matrix

The FPNV Positioning Matrix is pivotal in evaluating the Parkinson's Disease Therapeutics Market. It offers a comprehensive assessment of vendors, examining key metrics related to Business Strategy and Product Satisfaction. This in-depth analysis empowers users to make well-informed decisions aligned with their requirements. Based on the evaluation, the vendors are then categorized into four distinct quadrants representing varying levels of success: Forefront (F), Pathfinder (P), Niche (N), or Vital (V).

Market Share Analysis

The Market Share Analysis is a comprehensive tool that provides an insightful and in-depth examination of the current state of vendors in the Parkinson's Disease Therapeutics Market. By meticulously comparing and analyzing vendor contributions in terms of overall revenue, customer base, and other key metrics, we can offer companies a greater understanding of their performance and the challenges they face when competing for market share. Additionally, this analysis provides valuable insights into the competitive nature of the sector, including factors such as accumulation, fragmentation dominance, and amalgamation traits observed over the base year period studied. With this expanded level of detail, vendors can make more informed decisions and devise effective strategies to gain a competitive edge in the market.

Key Company Profiles

The report delves into recent significant developments in the Parkinson's Disease Therapeutics Market, highlighting leading vendors and their innovative profiles. These include Abbvie, Inc., Acadia Pharmaceuticals Inc., Amneal Pharmaceuticals, Inc., Apotex, Inc., Bausch Health Companies Inc., Boehringer Ingelheim International GmbH, Cipla Limited, DAIICHI SANKYO COMPANY, LIMITED, H. Lundbeck A/S, Mylan Inc. by Viatris Inc., Novartis AG, Orion Corporation, Sun Pharmaceutical Industries Limited, Teva Pharmaceuticals Industries Ltd., UCB S.A., and Wockhardt Limited.

Market Segmentation & Coverage

This research report categorizes the Parkinson's Disease Therapeutics Market to forecast the revenues and analyze trends in each of the following sub-markets:

Type
- Intestinal Infusion
- Oral
- Subcutaneous
- Transdermal
Drug Class
- Anticholinergic
- Carbidopa/Levodopa
- COMT Inhibitor
- Dopamine Receptor Agonist
- MAO Inhibitor
Distribution Channel
- Hospital Pharmacy
- Online Pharmacy
- Retailer Pharmacy
End Use
- Clinic
- Hospital

Region
- Americas
  - Argentina
  - Brazil
  - Canada
  - Mexico
  - United States
    - California
    - Florida
    - Illinois
    - New York
    - Ohio
    - Pennsylvania
    - Texas
- Asia-Pacific
  - Australia
  - China
  - India
  - Indonesia
  - Japan
  - Malaysia
  - Philippines
  - Singapore
  - South Korea
  - Taiwan
  - Thailand
  - Vietnam
- Europe, Middle East & Africa
  - Denmark
  - Egypt
  - Finland
  - France
  - Germany
  - Israel
  - Italy
  - Netherlands
  - Nigeria
  - Norway
  - Poland
  - Qatar
  - Russia
  - Saudi Arabia
  - South Africa
  - Spain
  - Sweden
  - Switzerland
  - Turkey
  - United Arab Emirates
  - United Kingdom

The report offers valuable insights on the following aspects:

Market Penetration: It presents comprehensive information on the market provided by key players.
Market Development: It delves deep into lucrative emerging markets and analyzes the penetration across mature market segments.
Market Diversification: It provides detailed information on new product launches, untapped geographic regions, recent developments, and investments.
Competitive Assessment & Intelligence: It conducts an exhaustive assessment of market shares, strategies, products, certifications, regulatory approvals, patent landscape, and manufacturing capabilities of the leading players.
Product Development & Innovation: It offers intelligent insights on future technologies, R&D activities, and breakthrough product developments.

The report addresses key questions such as:

What is the market size and forecast of the Parkinson's Disease Therapeutics Market?
Which products, segments, applications, and areas should one consider investing in over the forecast period in the Parkinson's Disease Therapeutics Market?
What are the technology trends and regulatory frameworks in the Parkinson's Disease Therapeutics Market?
What is the market share of the leading vendors in the Parkinson's Disease Therapeutics Market?
Which modes and strategic moves are suitable for entering the Parkinson's Disease Therapeutics Market?

Additional Product Information:

Purchase of this report includes 1 year online access with quarterly updates
This report can be updated on request. Please contact our Customer Experience team using the Ask a Question widget on our website

1. Preface

1.1. Objectives of the Study
1.2. Market Segmentation & Coverage
1.3. Years Considered for the Study
1.4. Currency & Pricing
1.5. Language
1.6. Limitations
1.7. Assumptions
1.8. Stakeholders

2. Research Methodology

2.1. Define: Research Objective
2.2. Determine: Research Design
2.3. Prepare: Research Instrument
2.4. Collect: Data Source
2.5. Analyze: Data Interpretation
2.6. Formulate: Data Verification
2.7. Publish: Research Report
2.8. Repeat: Report Update

3. Executive Summary

4. Market Overview

4.1. Introduction
4.2. Parkinson's Disease Therapeutics Market, by Region

5. Market Insights

5.1. Market Dynamics
5.1.1. Drivers
5.1.1.1. Growing prevalence of Parkinson’s disease among aging population
5.1.1.2. Development of new therapies and minimally invasive new devices
5.1.1.3. Strong drug pipeline under clinical research
5.1.2. Restraints
5.1.2.1. Availability of alternative treatments
5.1.3. Opportunities
5.1.3.1. Increasing pace of R&D by the government
5.1.3.2. Potential for pharmaceutical companies due to patent expiry
5.1.4. Challenges
5.1.4.1. Side effects of Parkinson's drugs
5.2. Market Segmentation Analysis
5.3. Market Trend Analysis
5.4. Cumulative Impact of High Inflation
5.5. Porter’s Five Forces Analysis
5.5.1. Threat of New Entrants
5.5.2. Threat of Substitutes
5.5.3. Bargaining Power of Customers
5.5.4. Bargaining Power of Suppliers
5.5.5. Industry Rivalry
5.6. Value Chain & Critical Path Analysis
5.7. Regulatory Framework

6. Parkinson's Disease Therapeutics Market, by Type

6.1. Introduction
6.2. Intestinal Infusion
6.3. Oral
6.4. Subcutaneous
6.5. Transdermal

7. Parkinson's Disease Therapeutics Market, by Drug Class

7.1. Introduction
7.2. Anticholinergic
7.3. Carbidopa/Levodopa
7.4. COMT Inhibitor
7.5. Dopamine Receptor Agonist
7.6. MAO Inhibitor

8. Parkinson's Disease Therapeutics Market, by Distribution Channel

8.1. Introduction
8.2. Hospital Pharmacy
8.3. Online Pharmacy
8.4. Retailer Pharmacy

9. Parkinson's Disease Therapeutics Market, by End Use

9.1. Introduction
9.2. Clinic
9.3. Hospital

10. Americas Parkinson's Disease Therapeutics Market

10.1. Introduction
10.2. Argentina
10.3. Brazil
10.4. Canada
10.5. Mexico
10.6. United States

11. Asia-Pacific Parkinson's Disease Therapeutics Market

11.1. Introduction
11.2. Australia
11.3. China
11.4. India
11.5. Indonesia
11.6. Japan
11.7. Malaysia
11.8. Philippines
11.9. Singapore
11.10. South Korea
11.11. Taiwan
11.12. Thailand
11.13. Vietnam

12. Europe, Middle East & Africa Parkinson's Disease Therapeutics Market

12.1. Introduction
12.2. Denmark
12.3. Egypt
12.4. Finland
12.5. France
12.6. Germany
12.7. Israel
12.8. Italy
12.9. Netherlands
12.10. Nigeria
12.11. Norway
12.12. Poland
12.13. Qatar
12.14. Russia
12.15. Saudi Arabia
12.16. South Africa
12.17. Spain
12.18. Sweden
12.19. Switzerland
12.20. Turkey
12.21. United Arab Emirates
12.22. United Kingdom

13. Competitive Landscape

13.1. FPNV Positioning Matrix
13.2. Market Share Analysis, By Key Player
13.3. Competitive Scenario Analysis, By Key Player

14. Competitive Portfolio

14.1. Key Company Profiles
14.1.1. Abbvie, Inc.
14.1.2. Acadia Pharmaceuticals Inc.
14.1.3. Amneal Pharmaceuticals, Inc.
14.1.4. Apotex, Inc.
14.1.5. Bausch Health Companies Inc.
14.1.6. Boehringer Ingelheim International GmbH
14.1.7. Cipla Limited
14.1.8. DAIICHI SANKYO COMPANY, LIMITED
14.1.9. H. Lundbeck A/S
14.1.10. Mylan Inc. by Viatris Inc.
14.1.11. Novartis AG
14.1.12. Orion Corporation
14.1.13. Sun Pharmaceutical Industries Limited
14.1.14. Teva Pharmaceuticals Industries Ltd.
14.1.15. UCB S.A.
14.1.16. Wockhardt Limited
14.2. Key Product Portfolio

15. Appendix

15.1. Discussion Guide
15.2. License & Pricing

List of Figures

FIGURE 1. PARKINSON'S DISEASE THERAPEUTICS MARKET RESEARCH PROCESS
FIGURE 2. PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, 2023 VS 2030
FIGURE 3. PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, 2018-2030 (USD MILLION)
FIGURE 4. PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY REGION, 2023 VS 2030 (%)
FIGURE 5. PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY REGION, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 6. PARKINSON'S DISEASE THERAPEUTICS MARKET DYNAMICS
FIGURE 7. PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY TYPE, 2023 VS 2030 (%)
FIGURE 8. PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY TYPE, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 9. PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2023 VS 2030 (%)
FIGURE 10. PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 11. PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2023 VS 2030 (%)
FIGURE 12. PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 13. PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY END USE, 2023 VS 2030 (%)
FIGURE 14. PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY END USE, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 15. AMERICAS PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
FIGURE 16. AMERICAS PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 17. UNITED STATES PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY STATE, 2023 VS 2030 (%)
FIGURE 18. UNITED STATES PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY STATE, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 19. ASIA-PACIFIC PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
FIGURE 20. ASIA-PACIFIC PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 21. EUROPE, MIDDLE EAST & AFRICA PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
FIGURE 22. EUROPE, MIDDLE EAST & AFRICA PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 23. PARKINSON'S DISEASE THERAPEUTICS MARKET, FPNV POSITIONING MATRIX, 2023
FIGURE 24. PARKINSON'S DISEASE THERAPEUTICS MARKET SHARE, BY KEY PLAYER, 2023

List of Tables

TABLE 1. PARKINSON'S DISEASE THERAPEUTICS MARKET SEGMENTATION & COVERAGE
TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2023
TABLE 3. PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, 2018-2030 (USD MILLION)
TABLE 4. GLOBAL PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY REGION, 2018-2030 (USD MILLION)
TABLE 5. PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
TABLE 6. PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY INTESTINAL INFUSION, BY REGION, 2018-2030 (USD MILLION)
TABLE 7. PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY ORAL, BY REGION, 2018-2030 (USD MILLION)
TABLE 8. PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY SUBCUTANEOUS, BY REGION, 2018-2030 (USD MILLION)
TABLE 9. PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY TRANSDERMAL, BY REGION, 2018-2030 (USD MILLION)
TABLE 10. PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 11. PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY ANTICHOLINERGIC, BY REGION, 2018-2030 (USD MILLION)
TABLE 12. PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY CARBIDOPA/LEVODOPA, BY REGION, 2018-2030 (USD MILLION)
TABLE 13. PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY COMT INHIBITOR, BY REGION, 2018-2030 (USD MILLION)
TABLE 14. PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY DOPAMINE RECEPTOR AGONIST, BY REGION, 2018-2030 (USD MILLION)
TABLE 15. PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY MAO INHIBITOR, BY REGION, 2018-2030 (USD MILLION)
TABLE 16. PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 17. PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY HOSPITAL PHARMACY, BY REGION, 2018-2030 (USD MILLION)
TABLE 18. PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY ONLINE PHARMACY, BY REGION, 2018-2030 (USD MILLION)
TABLE 19. PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY RETAILER PHARMACY, BY REGION, 2018-2030 (USD MILLION)
TABLE 20. PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY END USE, 2018-2030 (USD MILLION)
TABLE 21. PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY CLINIC, BY REGION, 2018-2030 (USD MILLION)
TABLE 22. PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY HOSPITAL, BY REGION, 2018-2030 (USD MILLION)
TABLE 23. AMERICAS PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
TABLE 24. AMERICAS PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 25. AMERICAS PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 26. AMERICAS PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY END USE, 2018-2030 (USD MILLION)
TABLE 27. AMERICAS PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
TABLE 28. ARGENTINA PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
TABLE 29. ARGENTINA PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 30. ARGENTINA PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 31. ARGENTINA PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY END USE, 2018-2030 (USD MILLION)
TABLE 32. BRAZIL PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
TABLE 33. BRAZIL PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 34. BRAZIL PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 35. BRAZIL PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY END USE, 2018-2030 (USD MILLION)
TABLE 36. CANADA PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
TABLE 37. CANADA PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 38. CANADA PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 39. CANADA PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY END USE, 2018-2030 (USD MILLION)
TABLE 40. MEXICO PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
TABLE 41. MEXICO PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 42. MEXICO PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 43. MEXICO PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY END USE, 2018-2030 (USD MILLION)
TABLE 44. UNITED STATES PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
TABLE 45. UNITED STATES PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 46. UNITED STATES PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 47. UNITED STATES PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY END USE, 2018-2030 (USD MILLION)
TABLE 48. UNITED STATES PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY STATE, 2018-2030 (USD MILLION)
TABLE 49. ASIA-PACIFIC PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
TABLE 50. ASIA-PACIFIC PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 51. ASIA-PACIFIC PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 52. ASIA-PACIFIC PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY END USE, 2018-2030 (USD MILLION)
TABLE 53. ASIA-PACIFIC PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
TABLE 54. AUSTRALIA PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
TABLE 55. AUSTRALIA PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 56. AUSTRALIA PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 57. AUSTRALIA PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY END USE, 2018-2030 (USD MILLION)
TABLE 58. CHINA PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
TABLE 59. CHINA PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 60. CHINA PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 61. CHINA PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY END USE, 2018-2030 (USD MILLION)
TABLE 62. INDIA PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
TABLE 63. INDIA PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 64. INDIA PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 65. INDIA PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY END USE, 2018-2030 (USD MILLION)
TABLE 66. INDONESIA PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
TABLE 67. INDONESIA PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 68. INDONESIA PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 69. INDONESIA PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY END USE, 2018-2030 (USD MILLION)
TABLE 70. JAPAN PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
TABLE 71. JAPAN PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 72. JAPAN PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 73. JAPAN PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY END USE, 2018-2030 (USD MILLION)
TABLE 74. MALAYSIA PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
TABLE 75. MALAYSIA PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 76. MALAYSIA PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 77. MALAYSIA PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY END USE, 2018-2030 (USD MILLION)
TABLE 78. PHILIPPINES PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
TABLE 79. PHILIPPINES PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 80. PHILIPPINES PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 81. PHILIPPINES PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY END USE, 2018-2030 (USD MILLION)
TABLE 82. SINGAPORE PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
TABLE 83. SINGAPORE PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 84. SINGAPORE PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 85. SINGAPORE PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY END USE, 2018-2030 (USD MILLION)
TABLE 86. SOUTH KOREA PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
TABLE 87. SOUTH KOREA PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 88. SOUTH KOREA PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 89. SOUTH KOREA PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY END USE, 2018-2030 (USD MILLION)
TABLE 90. TAIWAN PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
TABLE 91. TAIWAN PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 92. TAIWAN PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 93. TAIWAN PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY END USE, 2018-2030 (USD MILLION)
TABLE 94. THAILAND PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
TABLE 95. THAILAND PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 96. THAILAND PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 97. THAILAND PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY END USE, 2018-2030 (USD MILLION)
TABLE 98. VIETNAM PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
TABLE 99. VIETNAM PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 100. VIETNAM PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 101. VIETNAM PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY END USE, 2018-2030 (USD MILLION)
TABLE 102. EUROPE, MIDDLE EAST & AFRICA PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
TABLE 103. EUROPE, MIDDLE EAST & AFRICA PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 104. EUROPE, MIDDLE EAST & AFRICA PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 105. EUROPE, MIDDLE EAST & AFRICA PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY END USE, 2018-2030 (USD MILLION)
TABLE 106. EUROPE, MIDDLE EAST & AFRICA PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
TABLE 107. DENMARK PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
TABLE 108. DENMARK PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 109. DENMARK PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 110. DENMARK PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY END USE, 2018-2030 (USD MILLION)
TABLE 111. EGYPT PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
TABLE 112. EGYPT PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 113. EGYPT PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 114. EGYPT PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY END USE, 2018-2030 (USD MILLION)
TABLE 115. FINLAND PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
TABLE 116. FINLAND PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 117. FINLAND PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 118. FINLAND PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY END USE, 2018-2030 (USD MILLION)
TABLE 119. FRANCE PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
TABLE 120. FRANCE PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 121. FRANCE PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 122. FRANCE PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY END USE, 2018-2030 (USD MILLION)
TABLE 123. GERMANY PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
TABLE 124. GERMANY PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 125. GERMANY PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 126. GERMANY PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY END USE, 2018-2030 (USD MILLION)
TABLE 127. ISRAEL PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
TABLE 128. ISRAEL PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 129. ISRAEL PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 130. ISRAEL PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY END USE, 2018-2030 (USD MILLION)
TABLE 131. ITALY PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
TABLE 132. ITALY PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 133. ITALY PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 134. ITALY PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY END USE, 2018-2030 (USD MILLION)
TABLE 135. NETHERLANDS PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
TABLE 136. NETHERLANDS PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 137. NETHERLANDS PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 138. NETHERLANDS PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY END USE, 2018-2030 (USD MILLION)
TABLE 139. NIGERIA PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
TABLE 140. NIGERIA PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 141. NIGERIA PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 142. NIGERIA PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY END USE, 2018-2030 (USD MILLION)
TABLE 143. NORWAY PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
TABLE 144. NORWAY PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 145. NORWAY PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 146. NORWAY PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY END USE, 2018-2030 (USD MILLION)
TABLE 147. POLAND PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
TABLE 148. POLAND PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 149. POLAND PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 150. POLAND PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY END USE, 2018-2030 (USD MILLION)
TABLE 151. QATAR PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
TABLE 152. QATAR PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 153. QATAR PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 154. QATAR PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY END USE, 2018-2030 (USD MILLION)
TABLE 155. RUSSIA PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
TABLE 156. RUSSIA PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 157. RUSSIA PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 158. RUSSIA PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY END USE, 2018-2030 (USD MILLION)
TABLE 159. SAUDI ARABIA PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
TABLE 160. SAUDI ARABIA PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 161. SAUDI ARABIA PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 162. SAUDI ARABIA PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY END USE, 2018-2030 (USD MILLION)
TABLE 163. SOUTH AFRICA PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
TABLE 164. SOUTH AFRICA PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 165. SOUTH AFRICA PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 166. SOUTH AFRICA PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY END USE, 2018-2030 (USD MILLION)
TABLE 167. SPAIN PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
TABLE 168. SPAIN PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 169. SPAIN PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 170. SPAIN PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY END USE, 2018-2030 (USD MILLION)
TABLE 171. SWEDEN PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
TABLE 172. SWEDEN PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 173. SWEDEN PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 174. SWEDEN PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY END USE, 2018-2030 (USD MILLION)
TABLE 175. SWITZERLAND PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
TABLE 176. SWITZERLAND PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 177. SWITZERLAND PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 178. SWITZERLAND PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY END USE, 2018-2030 (USD MILLION)
TABLE 179. TURKEY PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
TABLE 180. TURKEY PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 181. TURKEY PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 182. TURKEY PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY END USE, 2018-2030 (USD MILLION)
TABLE 183. UNITED ARAB EMIRATES PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
TABLE 184. UNITED ARAB EMIRATES PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 185. UNITED ARAB EMIRATES PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 186. UNITED ARAB EMIRATES PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY END USE, 2018-2030 (USD MILLION)
TABLE 187. UNITED KINGDOM PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
TABLE 188. UNITED KINGDOM PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 189. UNITED KINGDOM PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 190. UNITED KINGDOM PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY END USE, 2018-2030 (USD MILLION)
TABLE 191. PARKINSON'S DISEASE THERAPEUTICS MARKET, FPNV POSITIONING MATRIX, 2023
TABLE 192. PARKINSON'S DISEASE THERAPEUTICS MARKET SHARE, BY KEY PLAYER, 2023
TABLE 193. PARKINSON'S DISEASE THERAPEUTICS MARKET LICENSE & PRICING

Companies Mentioned (Partial List)

A selection of companies mentioned in this report includes, but is not limited to:

Abbvie, Inc.
Acadia Pharmaceuticals Inc.
Amneal Pharmaceuticals, Inc.
Apotex, Inc.
Bausch Health Companies Inc.
Boehringer Ingelheim International GmbH
Cipla Limited
DAIICHI SANKYO COMPANY, LIMITED
H. Lundbeck A/S
Mylan Inc. by Viatris Inc.
Novartis AG
Orion Corporation
Sun Pharmaceutical Industries Limited
Teva Pharmaceuticals Industries Ltd.
UCB S.A.
Wockhardt Limited

Methodology

LOADING...

Table Information

Report Attribute	Details
No. of Pages	186
Published	March 2024
Forecast Period	2024 - 2030
Estimated Market Value ( USD ) in 2024	$ 7.21 Billion
Forecasted Market Value ( USD ) by 2030	$ 11.64 Billion
Compound Annual Growth Rate	8.2%
Regions Covered	Global

PURCHASE OPTIONS

Single User License PDF, Excel And Online Access

1 - 5 User License PDF, Excel And Online Access

Enterprise License PDF, Excel And Online Access

need a quote ?

License	Properties	Price
SINGLE USER LICENSE PDF, Excel and Online Access	This is a single user license, allowing one user access to the product.	€3678EUR$3,939USD£3,107GBP
1 - 5 USER LICENSE PDF, Excel and Online Access	This is a 1-5 user license, allowing up to five users have access to the product.	€4621EUR$4,949USD£3,903GBP
ENTERPRISE LICENSE PDF, Excel and Online Access	This is an enterprise license, allowing all employees within your organization access to the product.	€6507EUR$6,969USD£5,496GBP

FPNV Positioning Matrix

Market Share Analysis

Key Company Profiles

Market Segmentation & Coverage

The report offers valuable insights on the following aspects:

The report addresses key questions such as:

Table of Contents

Companies Mentioned (Partial List)

Methodology

Table Information

Related Topics

Related Reports

Anticholinergic Drugs Global Market Report 2024

Global Anticholinergic Drugs Market by Type (Natural, Semisynthetic, Synthetic), Application (Chronic Obstructive Pulmonary Disease, Gastrointestinal Disorders, Overactive Bladder), Route of Administration, Sales Channels - Forecast 2024-2030

Levodopa-Induced Dyskinesia (LID) - Market Insight, Epidemiology and Market Forecast - 2034

Levodopa-Induced Dyskinesia (LID) - Pipeline Insight, 2024

Anticholinergic Drugs - Global Strategic Business Report

About the Parkinson Drug Market